|
| |
| | Cancer Imatinib Prostate |
 | | AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase... | | | FDA) to market its cancer therapy Gleevec (imatinib mesylate) for the treatment... | | | ASH: Glivec (Imatinib Mesylate) Appears To Be Safe and Effective in bcr/abl Positive Chronic Myelogenous... |
|
http://www.cancer-directory.com/cancer/7/cancer-imatinib-prostate.html
(1238 words)
|
|
| |
| | Gleevec (imatinib mesylate) Drug Brief / RxPalace.com |
| | However, due to the high price tag of imatinib, it seems that the time has come to explore the exploitation of such drug interactions as a means of reducing medication cost. | | | Perhaps ketoconazole is not the ideal candidate for such use but it seems that a drug that is otherwise inert, that inhibits CYP3A4, could have a major role in reducing costs of drug therapy in general when co-administered with another CYP3A4 metabolized entity. | | | WebRx Editorial Notes: The manufacturer states, "It should be noted that the effectiveness of Gleevec is based on overall hematologic and cytogenetic response rates. |
|
http://www.rxpalace.com/DrugBriefs/Gleevec.htm
(555 words)
|
|
| |
| | imatinib mesylate - references in online news media |
| | While using a drug called imatinib mesylate (Gleevec) to treat leukaemia in the elderly last year, doctors from the Victor Segalen University in Bordeaux... | | | Imatinib mesylate appears to be active in patients with KIT-positive gastrointestinal stroma tumours (GISTs), but not in patients with other soft tissue... |
|
http://www.linkmorgue.org/DRUGS/nov03-nov04/imatinib_mesylate.html
(742 words)
|
|
| |
| | Imatinib -- Facts, Info, and Encyclopedia article |
| | Its development is the template for (Click link for more info and facts about rational drug design) rational drug design. | | | Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib. | | | Imatinib is a (A substance that is used as a medicine or narcotic) drug used to treat certain types of (Type genus of the family Cancridae) cancer. |
|
http://www.absoluteastronomy.com/encyclopedia/i/im/imatinib.htm
(992 words)
|
|
| |
| | Clinical Study: 02-I-0286, A Pilot Study of the Safety and Efficacy of Imatinib Mesylate in Reducing Eosinophilia in ... |
| | For the bone marrow procedure, an area of skin and bone is numbed and a very sharp needle is inserted into the bone to draw out a sample of bone marrow for evaluation under the microscope. | | | - Leukapheresis to study the effects of imatinib mesylate on eosinophils: For this procedure, whole blood is collected through a needle in an arm vein, similar to donating blood. | | | Imatinib mesylate is a new drug approved to treat gastrointestinal tumors and chronic myelogenous leukemia. |
|
http://clinicalstudies.info.nih.gov/detail/A_2002-I-0286.html
(1091 words)
|
|
| |
| | Gleevec (imatinib mesylate), chronic myeloid leukemia (CML) |
| | Imatinib mesylate was teratogenic in rats when administered during organogenesis at | | | RxUSA is a licensed Pharmacy, filling prescriptions for many medications. | | | Gleevec (imatinib mesylate) is indicated for the treatment of patients with chronic myeloid |
|
http://rxusa-gleevec-sales.com
(517 words)
|
|
| |
| | News - Sunitinib Prolongs Survival In GIST Patients After Imatinib Mesylate Failure - ECCO 13 |
| | Failure of imatinib mesylate therapy was either the result of resistance or intolerance. | | | Before sunitinib, there was no therapy of proven value for such patients, and this trial shows that sunitinib has documented benefits" | | | Newer therapies such as imatinib mesylate and sunitinib which interfere with growth factors and signal transduction proteins (tyrosine kinase inhibitors) are offering patients alternatives and prolonging patient survival. |
|
http://www.docguide.com/news/content.nsf/news/8525697700573E18852570AF00029F64
(1083 words)
|
|
| |
| | CML Support: Most Comprehensive Chronic Myelogenous Leukemia Information |
| | Your source for up-to-date news, information, commentary, and tips about imatinib mesylate (IM, Gleevec, Glivec) and chronic myelogenous leukemia. | | | Important New Paper: "Practical Management of Patients with Chronic Myeloid Leukemia Receiving Imatinib" | | | Read the latest medical journal articles about Gleevec and CML |
|
http://www.cmlsupport.com
(2174 words)
|
|
| |
| | IngentaConnect Serial Monitoring of BCR-ABL Transcripts in Chronic Myelogenous L... |
| | It is concluded that BCR-ABL mRNA quantification in peripheral blood is suitable for routine monitoring of the response to treatment and long-term disease status in CML, especially in patients who have achieved a complete cytogenetic response. | | | We have serially monitored peripheral blood and bone marrow BCR-ABL transcripts using qRT-PCR in CML patients commencing imatinib therapy, and compared the results with bone marrow cytogenetics. | | | Keywords: STI571; imatinib mesylate; chronic myelogenous leukemia; cytogenetics; PCR |
|
http://www.ingentaconnect.com/content/hum/mo/2004/00000021/00000004/art00008
(415 words)
|
|
| |
| | National Cancer Institute - Clinical Trials (PDQ®) |
| | Less than a major cytogenetic response after at least 6 months of imatinib mesylate treatment (cytogenetic response documented by karyotype or fluorescence in situ hybridization [FISH]) | | | Chronic or accelerated phase chronic myelogenous leukemia (CML) with 1 of the following: | | | Phase I Study of Flavopiridol and Imatinib Mesylate in Patients With Bcr/Abl+ Hematological Malignancies |
|
http://cancer.gov/clinicaltrials/MCV-NCI-6013
(538 words)
|
|
| |
| | BioMed Central Full text Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib ... |
| | We would postulate that the blood brain barrier might be disrupted in some individuals thereby allowing better penetration of the drug to the brain. | | | This is supported by clinical data from treatment of CML, where isolated cerebral relapses [4,5] have been described and low cerebrospinal fluid (CSF) levels of imatinib mesylate documented during therapy with the drug [6]. | | | The patient was commenced on imatinib mesylate (STI-571, Gleevec, Novartis) 400 mg bd in September 2001 as part of a clinical trial. |
|
http://www.biomedcentral.com/1471-2407/4/74
(2437 words)
|
|
| |
| | genome.gov NHGRI's Vision for the Future of Genomic Research |
| | This example offers promise that therapies based on genomic information will be particularly effective. | | | Drews, J. and Ryser, S. The role of innovation in drug development. | | | The success of imatinib mesylate (Gleevec), an inhibitor of the BCR-ABL tyrosine kinase, in treating chronic myelogenous leukaemia relied on a detailed molecular understanding of the disease's genetic cause |
|
http://www.genome.gov/11007524
(10492 words)
|
|
| |
| | Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. |
| | Clinical and translational data from these studies are likely to provide additional insights into the role of imatinib in combination therapy for prostate cancer. | | | Preclinical data suggest that preferential expression of PDGFRs in endothelial cells of tumor vasculature in experimental prostate cancer bone metastases is an important target for combination therapy incorporating the PDGFR inhibitor imatinib mesylate. | | | Because prostate cancer cells in bone metastases express the platelet-derived growth factor receptor (PDGFR), it is possible that inhibition of PDGFR can be an effective means of altering the clinical course of prostate cancer. |
|
http://www.pdg.cnb.uam.es/UniPub/iHOP/gp/10264061.html
(172 words)
|
|
| |
| | Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to ... |
| | Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance | | | Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms | | | Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms -- Dai et al. |
|
http://www.bloodjournal.org/cgi/content/abstract/104/2/509
(308 words)
|
|
| |
| | Gleevec |
| | New England Journal of Medicine Data Demonstrate Improved CML Response Rates With Gleevec(TM) (imatinib mesylate. | | | Experts to block UK use of leukaemia treatment. | | | Early Positive Gleevec (imatinib mesylate)* Data in Newly Diagnosed Chronic Myeloid Leukemia (CML) Study Prompt Major Protocol Changes. |
|
http://www.cptech.org/ip/health/gleevec
(821 words)
|
|
| |
| | Imatinib Mesylate |
| | Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. | | | Imatinib mesylate for the treatment of GIST is considered medically appropriate for individuals with: | | | Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. |
|
http://www.bcbst.com/MPManual/Imatinib_Mesylate.htm
(1114 words)
|
|
| |
| | Gleevec Indications, Dosage, Storage, Stability - Imatinib Mesylate - RxList Monographs |
| | (imatinib mesylate) is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for adult patients in accelerated phase or blast crisis. | | | Therapy should be initiated by a physician experienced in the treatment of patients with chronic myeloid leukemia or gastrointestinal stromal tumors. | | | Gleevec is also indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. |
|
http://www.rxlist.com/cgi/generic3/gleevec_ids.htm
(926 words)
|
|
| |
| | Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth ... |
| | Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. | | | Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits -- Leppänen et al. | | | Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits |
|
http://www.circulationaha.org/cgi/content/full/109/9/1140
(2962 words)
|
|
| |
| | National Cancer Institute - Clinical Trials (PDQ®) |
| | Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | | | Compare the rate of molecular response, as measured by the decrease in bcr-abl transcripts after 12 months of treatment, in patients with previously untreated chronic phase chronic myelogenous leukemia treated with imatinib mesylate at standard vs increased dose. | | | Phase II Randomized Study of Imatinib Mesylate at Standard Versus Increased Dose in Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia |
|
http://cancer.gov/clinicaltrials/SWOG-S0325
(711 words)
|
|
| |
| | Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcrabl-positive chronic myelogenous leukemia (CML) ... |
| | Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr | | | Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcrabl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) | | | The high rate of complete hematologic and complete cytogenetic responses in CP patients is remarkable, as intensive treatment approaches plus IFN-alpha failed to be efficient in achieving long-term stabilization of CML in this patient cohort. |
|
http://www.nature.com/doifinder/10.1038/sj.leu.2402565
(337 words)
|
|
| |
| | Glivec International - Glivec, GIST, and CML Info for HCPs |
| | "Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience" | | | New Data on Long-Term Response to Imatinib and Implications of Rationale for Higher Dose Therapy in Ph+ CML | | | "The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long term outcome of treatment with imatinib mesylate" |
|
http://www.glivec.com
(218 words)
|
|
| |
| | Newly Approved Drug Therapies (735): Gleevec (imatinib mesylate), Novartis |
| | Newly Approved Drug Therapies (735): Gleevec (imatinib mesylate), Novartis | | | The brand name Gleevec is used in the United States, whereas the drug is referred to as Glivec outside the United States. | | | In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-kit mutation. |
|
http://www.centerwatch.com/patient/drugs/dru735.html
(387 words)
|
|
| |
| | Chronic Myelogenous Leukemia (CML) |
| | But now treatment with the drug imatinib mesylate (Gleevec® also known STI571) appears to be able to cure the disease. | | | Until recently, the only successful treatment of CML was to destroy the patient's bone marrow and then restore blood-cell production by infusing stem cells from the bone marrow of a healthy donor. |
|
http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CML.html
(753 words)
|
|
| |
| | Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. |
| | The values for the concentration that inhibits 50% (IC(50)) of T-cell proliferation stimulated by dendritic cells and PHA were 3.9 microM and 2.9 microM, respectively, that is, within the concentration range found in patients treated with imatinib mesylate. | | | The in vitro observations were confirmed in vivo in a murine model of delayed-type hypersensitivity (DTH). | | | Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.In mice treated with imatinib mesylate, DTH was reduced in comparison to sham-injected controls. |
|
http://www.pdg.cnb.uam.es/UniPub/iHOP/gp/10490421.html
(232 words)
|
|
| |
| | News - Imatinib Mesylate Promising in Advanced Gastrointestinal Stromal Tumours |
| | For technical reasons, response could not be evaluated in seven patients (4.8 percent). | | | Preclinical models and preliminary clinical studies have shown imatinib mesylate - a selective tyrosine kinase inhibitor-to have activity against GI stromal tumours. | | | Inhibition of the KIT signal-transduction pathway is showing promise in the treatment of advanced gastrointestinal (GI) tumours |
|
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C16000793D4
(467 words)
|
|
| |
| | Gleevec Online, Description, Chemistry, Ingredients - Imatinib Mesylate - RxList Monographs |
| | In non-aqueous solvents, the drug substance is freely soluble to very slightly soluble in dimethyl sulfoxide, methanol and ethanol, but is insoluble in n-octanol, acetone and acetonitrile. | | | Imatinib mesylate is designated chemically as 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-yrimidinyl]amino]-phenyl]benzamide methanesulfonate and its structural formula is: | | | (imatinib mesylate) film-coated tablets contain imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base. |
|
http://www.rxlist.com/cgi/generic3/gleevec.htm
(171 words)
|
|
| |
| | Mayo Clinic Researchers Successfully Use Anticancer Drug To Fight Fatal Lung Disease, Idiopathic Pulmonary Fibrosis |
| | Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. | | | ROCHESTER, Minn. — Mayo Clinic researchers have identified a treatment for the fatal lung disease idiopathic pulmonary fibrosis (IPF). | | | They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. |
|
http://www.sciencedaily.com/releases/2004/11/041108020203.htm
(924 words)
|
|
| |
| | [Brainlife] HOLDHOFF M et al (2004) - Combined administration of imatinib mesylate and ionizing radiation leads to ... |
| | Because of the specific target profile of this orally available and generally well tolerated drug, imatinib is under intensive investigation for the potential treatment of other diseases. | | | Immunoprecipitation was performed to assess inhibition of the different kinases by imatinib mesylate. | | | The selective tyrosine kinase inhibitor imatinib mesylate (Gleevec) effectively inhibits the activity of the abl, PDGF receptor (PDGFR) and c-kit tyrosine kinases. |
|
http://www.brainlife.org/abstract/holdhoff_2004.htm
(475 words)
|
|
| |
| | PR Newswire : Novartis Submits Supplemental NDA with U.S. Food and Drug Administration for Gleevec(TM) (imatinib ... |
| | Novartis announced today that it has submitted a supplementary New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), seeking marketing authorization for its novel drug Gleevec(TM) (imatinib mesylate) for the treatment of patients with unresectable (inoperable) and/or metastatic malignant gastrointestinal stromal tumors (GISTs). | | | Novartis Submits Supplemental NDA with U.S. Food and Drug Administration for Gleevec(TM) (imatinib mesylate)* for Treatment of Certain GI Tumors. | | | Current Article: Novartis Submits Supplemental NDA with U.S. Food and Drug Administration for Gleevec(TM) (imatinib mesylate)* for Treatment of Certain GI Tumors. |
|
http://static.elibrary.com/p/prnewswire/october192001/novartissubmitssupplementalndawithusfoodanddrugadm/index.html
(256 words)
|
|
| |
| | CiteULike: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer |
| | A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer | | | CiteULike: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer | | | Modi S, Seidman A, Dickler M, Moasser M, D'Andrea G, Moynahan M, Menell J, Panageas K, Tan L, Norton L, Hudis C |
|
http://www.citeulike.org/article/155459
(86 words)
|
|
| |
| | ipedia.com: Cytogenetics Article |
| | In some forms of cancer, especially hematological malignancies, cytogenetics can determine which chromosomal translocations are present in the malignant cells, facilitating diagnosis and susceptibility to treatment (e.g. | | | In congenital disorders, such as Down's syndrome, cytogenetics can determine the nature of the chromosomal defect - a "simple" trisomy, a mosaic or a "balanced" translocation in one - or both - of the parents. | | | imatinib mesylate in the presence of the Philadelphia chromosome). |
|
http://www.ipedia.com/cytogenetics.html
(173 words)
|
|
|
